Allogenic blood is from another donor; autologous is blood the patient donates for his/her own use.
Policy
BCBSVT will provide coverage for transfusion services of whole blood, blood components, and blood derivatives when ordered by the member's physician under circumstances where the transfusion of blood or blood products is an accepted medical practice and is therefore considered medically necessary.* * BCBSVT may request medical records for retrospective determination of medical necessity.
Use of autologous blood-derived preparations (i.e., platelet-rich plasma, autologous blood injections, autologous platelet rich plasma gel, bone marrow plasma injections) is considered investigational for all indications including, but not limited to, use in the following situations:
• Treatment of acute or chronic wounds including nonhealing ulcers, dehiscent wounds, bone healing;
• Adjunctive use in surgical procedures;
• Primary use (injection) for other conditions such as epicondylitis (i.e., tennis elbow), plantar fasciitis, or Dupuytren's contracture and other tendinopathies;
• As a component of prolotherapy (The goal of prolotherapy is to promote tissue repair or growth by prompting release of growth factors, such as cytokines, or by increasing the effectiveness of existing circulating growth factors. The mechanism of action is not well understood but may involve local irritation and/or cell lysis. Prolotherapy in any form is considered investigational.)
Administrative and Contractual Guidance Benefit Determination Guidance
Benefits are subject to all terms, limitations and conditions of the subscriber contract.
Federal Employee Program (FEP) members may have different benefits that apply. For further information please contact FEP customer service or refer to the FEP Service Plan Brochure.
The Plan will not provide coverage for:
• Storage of whole blood, blood components or blood derivatives.
• Testing of blood the patient donates for his or her own use (even if the blood is used),
• Whole blood, blood components or blood derivatives when it is not included as part of the transfusion service.
Charges for transfusion services (excluding storage) for blood derivatives are eligible for coverage as supplies or laboratory services. Charges for blood derivatives, which are classified as formulary drugs (i.e., hemophilia factors), are eligible for coverage as prescription drugs.
If the autologous blood is not used by the donor and becomes part of the blood bank supply, the cost of testing should be passed on to the ultimate recipient as an allogenic transfusion. 
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Related Policies
Scientific Background and Reference Resources
The literature on prolotherapy consists of small randomized trials on a variety of pain syndromes, with inconsistent results. The body of scientific evidence does not permit conclusions concerning the effect of prolotherapy on health outcomes for chronic neck or back pain, tendinopathies of the upper or lower limbs, osteoarthritic pain, or other musculoskeletal pain conditions.
